The global mice model market size surpassed USD 10.17 billion in 2023 and is estimated to increase from USD 10.78 billion in 2024 to approximately USD 19.36 billion by 2034. It is projected to grow at a CAGR of 6.03% from 2024 to 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Mice Model Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Mice Model Market Revenue and Volume, By Mice, 2024-2033
8.1.1 Inbred
8.1.1.1. Market Revenue and Volume Forecast (2021-2033)
8.1.2. Outbred
8.1.2.1. Market Revenue and Volume Forecast (2021-2033)
8.1.3. Knockout
8.1.3.1. Market Revenue and Volume Forecast (2021-2033)
8.1.4. Hybrid
8.1.4.1. Market Revenue and Volume Forecast (2021-2033)
8.1.5. Other Mice
8.1.5.1. Market Revenue and Volume Forecast (2021-2033)
9.1. Mice Model Market Revenue and Volume, By Technology, 2024-2033
9.1.1. CRISPR
9.1.1.1. Market Revenue and Volume Forecast (2021-2033)
9.1.2. Microinjection
9.1.2.1. Market Revenue and Volume Forecast (2021-2033)
9.1.3. Embryonic Stem Cell Injection
9.1.3.1. Market Revenue and Volume Forecast (2021-2033)
9.1.4. Nuclear Transfer
9.1.4.1. Market Revenue and Volume Forecast (2021-2033)
9.1.5. Other Technologies
9.1.5.1. Market Revenue and Volume Forecast (2021-2033)
10.1. North America
10.1.1. Market Revenue and Volume Forecast, By Mice (2021-2033)
10.1.2. Market Revenue and Volume Forecast, By Technology (2021-2033)
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, By Mice (2021-2033)
10.1.3.2. Market Revenue and Volume Forecast, By Technology (2021-2033)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, By Mice (2021-2033)
10.1.4.2. Market Revenue and Volume Forecast, By Technology (2021-2033)
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, By Mice (2021-2033)
10.2.2. Market Revenue and Volume Forecast, By Technology (2021-2033)
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, By Mice (2021-2033)
10.2.3.2. Market Revenue and Volume Forecast, By Technology (2021-2033)
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, By Mice (2021-2033)
10.2.4.2. Market Revenue and Volume Forecast, By Technology (2021-2033)
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, By Mice (2021-2033)
10.2.5.2. Market Revenue and Volume Forecast, By Technology (2021-2033)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, By Mice (2021-2033)
10.2.6.2. Market Revenue and Volume Forecast, By Technology (2021-2033)
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, By Mice (2021-2033)
10.3.2. Market Revenue and Volume Forecast, By Technology (2021-2033)
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, By Mice (2021-2033)
10.3.3.2. Market Revenue and Volume Forecast, By Technology (2021-2033)
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, By Mice (2021-2033)
10.3.4.2. Market Revenue and Volume Forecast, By Technology (2021-2033)
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, By Mice (2021-2033)
10.3.5.2. Market Revenue and Volume Forecast, By Technology (2021-2033)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, By Mice (2021-2033)
10.3.6.2. Market Revenue and Volume Forecast, By Technology (2021-2033)
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, By Mice (2021-2033)
10.4.2. Market Revenue and Volume Forecast, By Technology (2021-2033)
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, By Mice (2021-2033)
10.4.3.2. Market Revenue and Volume Forecast, By Technology (2021-2033)
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, By Mice (2021-2033)
10.4.4.2. Market Revenue and Volume Forecast, By Technology (2021-2033)
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, By Mice (2021-2033)
10.4.5.2. Market Revenue and Volume Forecast, By Technology (2021-2033)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, By Mice (2021-2033)
10.4.6.2. Market Revenue and Volume Forecast, By Technology (2021-2033)
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, By Mice (2021-2033)
10.5.2. Market Revenue and Volume Forecast, By Technology (2021-2033)
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, By Mice (2021-2033)
10.5.3.2. Market Revenue and Volume Forecast, By Technology (2021-2033)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, By Mice (2021-2033)
10.5.4.2. Market Revenue and Volume Forecast, By Technology (2021-2033)
11.1. Trans Genic Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. The Jackson Laboratory
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Taconic Biosciences, Inc.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Sage Labs
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. PolyGene
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Ozgene Pty Ltd
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Janvier Labs
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Inotiv
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Hera Biolabs
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Harbour Biomed
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample